Medically reviewed by Jonathan Purtell, RDN Healthy food choices can help manage MASH, short for metabolic ...

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

Histoindex Pte Ltd. launched its laboratory-developed test for metabolic dysfunction-associated steatohepatitis (MASH), ...

PathAI, a global leader in AI-powered pathology, today announced that the European Medicines Agency (EMA) Committee for ...

Machine learning may help identify biomarkers and develop predictive models that could assist in the diagnosis of metabolic ...

MetaVia Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the year ended December 31, 2024 and provided a corporate ...

Understanding liver fibrosis progression through machine learning provides valuable insights into disease mechanisms, ...

MASH has long been a challenging and progressive liver disease, characterized by fat build-up and inflammation that, if left ...

Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025Commercial launch in the PRC of generic nintedanib for the ...

Reports Q4 revenue $ $27.87M consensus $23.5M…”2025 is shaping up to be a pivotal year for Gyre across both our commercial-stage and ...

Explore the promising potential of Altimmune, Inc.'s Pemvidutide in NASH, AUD, & obesity treatment, with key trials underway.

FibroScan overestimated advanced fibrosis and cirrhosis in patients with class 3 obesity and metabolic dysfunction-associated steatotic liver disease.